EGFR and non-small cell lung carcinoma: With regard to PD-L1, Meniawy (39) and Arrieta (40) demonstrate higher proportions of PD-L1+ CD3+ T cells in patients with non-small cell lung cancer (NSCLC) and a correlation between PD-L1 expression on peripheral T cells and clinical outcomes in EGFR-TKI-treated NSCLC.